Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

Research led by CU cardiologist Marc Bonaca, MD, is a step forward in improving treatment options for patients with peripheral artery disease and type 2 diabetes, revealing that semaglutide ...

CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including ...

CHICAGO — Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless of baseline diabetes duration, HbA1c, BMI and concomitant ...

(HealthDay News) — For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased walking distance, according to a study published ...

Common obesity drug reduced the risk of disease progression by 54% . CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with ...

Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with ...